Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205869 | 0.78 | PDE4B (0.56) | HPGDCYP1A2CYP2C9MAPTLMNA | |
| SCHEMBL1779841 | 0.78 | HDAC1 (0.42) | HPGDCYP1A2CYP2C9MAPTL3MBTL1 | |
| SCHEMBL3077151 | 0.77 | ALDH1A1 (0.40) | HPGDCYP1A2CYP2C9MAPTL3MBTL1 | |
| Formamide SCHEMBL15017827 | 0.77 | PDE5A (0.41) | CYP1A2CYP2C9MAPTLMNAHTT | |
| SCHEMBL8811759 | 0.76 | ADORA2A (0.45) | LMNAALDH1A1ADORA2AADORA1HDAC1 | |
| SCHEMBL1780822 | 0.76 | ALDH1A1 (0.38) | HPGDCYP1A2CYP2C9MAPTL3MBTL1 | |
| SCHEMBL25375024 | 0.75 | ALDH1A1 (0.42) | HPGDCYP1A2CYP2C9MAPTL3MBTL1 | |
| SCHEMBL6490727 | 0.75 | PDE5A (0.44) | CYP1A2CYP2C9MEN1KMT2AALDH1A1 | |
| SCHEMBL3077262 | 0.75 | HPGD (0.34) | HPGDCYP1A2CYP2C9MAPTL3MBTL1 | |
| SCHEMBL31597368 | 0.75 | DRD2 (0.34) | HPGDCYP1A2CYP2C9MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | claimed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | claimed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11702419-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-07-18 | — | — | US | disclosed |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
| US-20070161653-A1 | Pyrazolo-Pyridine Derivatives As Antiherpes Agents | GUDMUNDSSON KRISTJAN | 2007-07-12 | — | — | US | disclosed |
| US-7199120-B2 | Pyrazolo-pyridine derivatives as antiherpes agents | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| EP-0270926-B1 | AGENTS PROMOTING THE ACTIVITY OF SOME ANTITUMOR AGENTS AND METHODS FOR THEIR PRODUCTION | KYORIN SEIYAKU KABUSHIKI KAISHA (JP) | 1993-03-17 | — | — | EP | disclosed |
| US-4923871-A | ANTITUMOR | KYORIN SEIYAKU KABUSHIKI KAISHA (JP) | 1990-05-08 | — | — | US | disclosed |
| EP-0270926-A2 | Agents promoting the activity of some antitumor agents and methods for their production | KYORIN SEIYAKU KABUSHIKI KAISHA (JP) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HPGD 1080/4885CYP1A2 767/4885CYP2C9 773/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | HPGD 815/4885CYP1A2 611/4885CYP2C9 694/4885 |
| US-20070161653-A1 | Pyrazolo-Pyridine Derivatives As Antiherpes Agents | HRH4, HRH2, HRH1 | HPGD 98/4885CYP1A2 20/4885CYP2C9 39/4885 |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | HPGD 281/4885CYP1A2 787/4885CYP2C9 1354/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | HPGD 1080/4885CYP1A2 767/4885CYP2C9 773/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HPGD 1080/4885CYP1A2 767/4885CYP2C9 773/4885 |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HPGD 1080/4885CYP1A2 767/4885CYP2C9 773/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | HPGD 1749/4885CYP1A2 540/4885CYP2C9 1000/4885 |
| US-11702419-B2 | Heterocyclic compound and use thereof | GRIN2B, GRIN2A, GRIN2C | HPGD 507/4885CYP1A2 2691/4885CYP2C9 2002/4885 |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | HPGD 1538/4885CYP1A2 1772/4885CYP2C9 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.